Navigation Links
BioNeutral's Ygiene(TM) Hospital Grade Achieves World Class Independent Test Results in Killing Life Threatening Spores/Organisms
Date:7/13/2009

omings by being ineffective, cumbersome to use or require very lengthy periods of time to be effective at all in eliminating health threatening spores.

A room temperature, cold, sporicide/sterilant with the rapid kill demonstrated by Ygiene(TM) Hospital Grade will provide a huge economic advantage for future users. By delivering a safe easy to use and a much quicker turn around time for total sterilization of equipment and facilities, BioNeutrals Ygiene(TM) will greatly reduce the waste of human resources and capital currently experienced in health care facilities and will maximize value to the user & increased safety for the patients.

Dr. Andy Kielbania PhD, Chief Scientist at BioNeutral Group stated: "These independent lab validation results from ATS show that we have developed what we believe is the best, and I emphasize the best, antimicrobial coming to the market. By using the strategy of raising the bar for antimicrobial performance, we believe our superior Ygiene(TM) Hospital Grade antimicrobial will provide much cleaner, safer and healthier environments in health care facilities globally. Reducing the loss of lives and wasteful expenditures of human resources and money by diminishing Hospital Acquired Infections (ACI) is our goal. These independent test results stand by themselves and are consistent with our achieving our goals and objectives. These results are incredible and validate all of our efforts."

Dr. Philip M. Tierno Jr. MS, PhD Chairman of BioNeutral Group Scientific Advisory Board stated: "The sporocidal data on Ygiene(TM)'s performance that I reviewed is quite impressive. Two immediate and important applications of Ygiene(TM) come to mind:

1- Perhaps the biggest challenge facing hospitals worldwide is eradication of Clostridium difficile spores in the environment in a timely fashion thereby reducing or eliminating possible nosocomial spread. Ygiene(TM) safely and e
'/>"/>

SOURCE BioNeutral Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioNeutrals Ygiene(TM) Hospital Grade Antimicrobial Demonstrates a 99.9997% Kill Rate Against Clostridium Difficile Spores (C.diff) in Independent Lab Pre-testing Phase
2. BioNeutrals Ygiene(TM) New Hospital Grade Disinfectant Will Save Lives and Billions of Dollars Annually at Health Care Facilities Around the World
3. Stem Cell Cord Blood Banking Is Huge Global Business for Hospitals, Says CEO of Bio-Matrix Scientific Group Inc.
4. Galichia Heart Hospital Partners with Mobile Surgery International to Develop Wichita-based Center of Excellence with Global Convenience(TM)
5. GeoVax Signs HIV/AIDS Vaccine Proposal With Health and Hospital System of Cook County, Illinois
6. Cumberland Pharmaceuticals Provides Hospital In-Service Webcast for Acetadote(R)
7. Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Childrens Hospital Boston and Massachusetts General Hospital
8. CPM Resource Center and The Shams Group Partner To Help Hospitals Integrate Evidence-Based Clinical Content Into Information Systems
9. University of Illinois Medical Center in Chicago First Hospital to Install Innovative Shape-HF™ Cardiopulmonary Testing System
10. New Hospital Energy Performance Service Helps Hospitals Cut Energy Costs by 25% or More
11. TeleHealth Services Chosen by Baptist Hospital East in Development of New Park Tower
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... Texas , May 29, 2015  Caris ... focused on fulfilling the promise of precision medicine, ... studies that demonstrate the clinical utility of Caris ... tumor profiling service, in helping to identify targeted ... tumors. In each of the studies, results of ...
(Date:5/29/2015)... 29, 2015 Seoul Semiconductor (CEO: ... LED technology, on May 28th announced that it ... by strengthening its high efficient and high reliable ... Since 2011 Seoul Semiconductor has developed efficient and ... and has supplied LEDs for headlamps to global ...
(Date:5/28/2015)... May 28, 2015  Quest Diagnostics Incorporated (NYSE: ... services, announced that it is scheduled to speak at ... Steve Rusckowski , the company,s President and CEO, ... strategy.  The presentation is scheduled for Tuesday, June 2, ... presentation will be webcast live during the conference and ...
(Date:5/28/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/6cg3zw/cell_therapy ) has announced ... "Cell Therapy - Technologies, Markets and Companies" ... and evaluates cell therapy technologies and methods, which ... in the practice of medicine. Hematopoietic stem cell ... transplants. Role of cells in drug discovery is ...
Breaking Biology Technology:Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 2Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 3Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 4Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 5Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 6Seoul Semiconductor Increases the Global Automotive LED Market Share with its High Efficient and Reliable LEDs for Automotive Lightings 2Quest Diagnostics to Speak at the Jefferies 2015 Global Healthcare Conference 2Global Cell Therapy Market 2015-2020 - Technologies, Markets and Companies 2
... Genoptix, Inc.,(Nasdaq: GXDX ), a specialized ... the BIOCOM Investor Conference 2008,scheduled to take place ... on October,26-28, 2008., Dr. Tina Nova, President ... on Monday, October 27, beginning at approximately 9:30 ...
... ... - Results Presented at the 20th EORTC-NCI-AACR Symposium on Molecular ... Targets and Cancer Therapeutics -, GENEVA and SAN FRANCISCO, ... new data from an,ongoing Phase 1-2 clinical trial demonstrating that the Company,s novel,androgen ...
... Presented at 20th EORTC-NCI-AACR Symposium -, ... 22 /PRNewswire-FirstCall/,-- Poniard Pharmaceuticals, Inc. (Nasdaq: ... today announced positive incremental data from,its randomized, ... in patients,with metastatic colorectal cancer (CRC). The ...
Cached Biology Technology:Genoptix Announces Participation at the BIOCOM Investor Conference 2008 2Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients 2Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients 3Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients 4Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer 2Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer 3Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer 4Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer 5
(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
(Date:5/6/2015)... 2015 LifeBEAM, a developer of bio-sensing technology, ... today that they will expand their partnership in bio-sensing ... cycling helmet and the first joint project between the ... in order to give cyclists more style choices and ... and Lazer announced their plan to release a new ...
(Date:4/27/2015)... , Apr. 27, 2015 Profile Solutions, Inc. ... and security systems is pleased to announce that Dr ... a consultant and member of its scientific advisory board. ... known as a thought leader in technology-enhanced learning models. ... Group, and has published studies and books focused on ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... Testing people for heart disease might be just a finger ... by a team of researchers from Harvard and Northeastern universities ... FASEB Journal ( http://www.fasebj.org ), they describe how ... needed to build vascular tissue, called endothelial progenitor cells, using ...
... Boston, MA June 1, 2009 REGiMMUNE ... in combination with a low-dose of Sirolimus, demonstrated enhanced ... transplantation and acute Graft-versus-Host disease (GvHD). This data ... Tolerance Induction by a Liposomal Formulation of KRN7000 (RGI-2001) ...
... species are likely to respond to climate change. Most ... and the interactions between species, in the interest of ... BioScience , by Eric Post of Pennsylvania State University ... avoided. Their approach, which relies on multi-stage analyses of ...
Cached Biology News:New device detects heart disease using less than one drop of blood 2REGiMMUNE presents enhanced efficacy data in preclinical transplantation models 2
Buckets for tube holder inserts...
45° Fixed Angle Rotor for use in the IEC Centra CL2, Centra CL3/CL3R, HN-SII, and the Centra-MP4/MP4R....
... 10-2 is a microprocessor controlled, high ... coupled with exceptionally smooth operation make ... applications involving fluorescence microscopy, ratio imaging, ... requiring rapid and accurate aperture positioning. ...
... Fluoroskan Ascent FL is ... and luminometric measurement technologies ... list of advanced features ... Luminoskan Ascent. Fluoroskan Ascent ...
Biology Products: